Printer Friendly

P&G AND HOUGHTEN PHARMACEUTICALS INC. SIGN JOINT RESEARCH AGREEMENT

 P&G AND HOUGHTEN PHARMACEUTICALS INC.
 SIGN JOINT RESEARCH AGREEMENT
 CINCINNATI, May 27 /PRNewswire/ -- The Procter & Gamble Company (NYSE: PG) and Houghten Pharmaceuticals, Inc. (HPI) today announced they have signed a joint research and development agreement involving HPI's proprietary peptide screening drug technology -- a revolutionary new way to speed up the drug discovery process.
 Under the terms of the agreement, P&G and HPI (formerly Iterex Pharmaceuticals) will conduct joint research in a number of therapeutic areas related to P&G's health care products business. Specific terms of the agreement are not being disclosed. However, the agreement provides for HPI to receive an up-front payment, and to share in resulting profits on jointly developed products.
 Peptides are natural proteins which play a key role in the regulation of many human physiological functions, including blood pressure, inflammation, control or modulation of pain, and fertility. Peptides can be used in place of more complex molecules traditionally used in conventional drug design, and can be applied to virtually any disease area.
 While peptide drugs are not new, HPI's peptide screening technology allows for more rapid drug discovery of new drugs. It can rapidly generate and screen millions of peptides in only a matter of weeks or months, rather than years.
 "Research agreements, such as this one with Houghten Pharmaceuticals, are important to the future growth of our health care products business," said Gordon F. Brunner, senior vice president of research and development for Procter & Gamble. "HPI is a pioneer in this field of drug design, and this agreement will help insure that P&G is in the forefront of drug discovery technology."
 "We are very pleased to begin an affiliation with Procter & Gamble, particularly at a time when P&G is expanding its presence in the health care field," said Richard A. Houghten, Ph.D., HPI president and chief executive officer. "By combining our resources, we are confident we will be able to make rapid progress toward development of a variety of useful pharmaceutical products."
 Based in Cincinnati, Procter & Gamble makes and markets a wide range of products for consumers and industry, including various over- the-counter and prescription health care products. For fiscal 1990- 91, P&G had worldwide sales of $27 billion and invested $786 million in research and development.
 San Diego-based Houghten Pharmaceuticals Inc. plans to use its peptide screening technology to discover and develop its own portfolio of proprietary peptide pharmaceutical partners in areas outside its field of interest.
 -0- 5/27/92
 /CONTACT: Cindy Weigle of Houghten Pharmaceuticals, 619-453-7700; or Donald P. Tassone of Procter & Gamble, 513-983-4271/
 (PG) CO: Procter & Gamble; Houghten Pharmaceuticals, Inc. ST: Ohio, California IN: MTC SU: JVN


KK -- CL004 -- 4089 05/27/92 08:49 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1992
Words:451
Previous Article:CONTROL DATA PLANS TO SEPARATE INTO TWO COMPANIES
Next Article:MEDICAL TECHNOLOGY SYSTEMS EXTENDS MSYSW WARRANTS TO AUGUST 15
Topics:


Related Articles
THE LIPOSOME COMPANY AND MERCK EXTEND AIDS RESEARCH AGREEMENT
GLAXO INC., HOUGHTEN PHARMACEUTICALS SIGN JOINT RESEARCH, DEVELOPMENT AGREEMENT USING PATENTED PEPTIDE TECHNOLOGY IN DRUG DISCOVERY
AMERICAN CYANAMID, HOUGHTEN PHARMACEUTICALS SIGN RESEARCH COLLABORATION AGREEMENT
HOUGHTEN PHARMACEUTICALS INC. AND NORTHWEST NEUROLOGIC INC. SIGN RESEARCH & LICENSE AGREEMENT FOR RESEARCH COLLABORATION
P&G AND HOUGHTEN PHARMACEUTICALS INITIATE THIRD DRUG DISCOVERY ALLIANCE
P&G AND HOUGHTEN PHARMACEUTICALS INITIATE THIRD DRUG DISCOVERY ALLIANCE
DURA PHARMACEUTICALS, INC. SIGNS COLLABORATIVE AGREEMENT WITH HOUGHTEN PHARMACEUTICALS, INC.
Magainin Pharmaceuticals Buys Out MSI-78 Royalty Stream
Trega Biosciences and TPIMS Extend Combinatorial Chemistry Agreement
Trega and Ono Establish R&D Partnership

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters